Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

Marlise R. Luskin, Mark Alan Murakami, Julia H. Keating, Yael Flamand, Eric S Winer, Jacqueline S. Garcia, Maximilian Stahl, Richard M. Stone, Martha Wadleigh, Stella Louise Jaeckle, Ella Hagopian, David M. Weinstock, Jessica Liegel, Malgorzata McMasters, Eunice S Wang, Wendy Stock, Daniel J DeAngelo

Blood blood.2024025800.

https://doi.org/10.1182/blood.2024025800

Published: 2024

Includes: Supplemental data

Journal Articles

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Hari S. Raman, Shai Shimony, Yannis K. Valtis, Yael Flamand, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna S. Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin

Blood (2023) 142 (Supplement 1): 1456.

https://doi.org/10.1182/blood-2023-178353

Published: 2023

Journal Articles

Oral Chemotherapy Adherence in Pediatric Acute Lymphoblastic Leukemia (ALL): A Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 16-001

Justine M. Kahn, Hital Patel, Julia Keating, Yael Flamand, Victoria Koch, Peter D. Cole, Lisa M. Gennarini, Bruno Michon, Thai Hoa Tran, Jennifer J.G. Welch, Lewis B. Silverman, Elizabeth Bouchard, Kira Bona, Kara M. Kelly

Blood (2023) 142 (Supplement 1): 7375.

https://doi.org/10.1182/blood-2023-189447

Published: 2023

Journal Articles

Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL

Marlise R. Luskin, Shai Shimony, Julia Keating, Wendy Stock, Hanno Hock, Jacqueline S. Garcia, Maximilian Stahl, Ilene Galinksy, Rebecca Leonard, Howard Weiner, Yael Flamand, Donna S. Neuberg, Richard M Stone, Anthony G. Letai, Eric S. Winer, Marina Y. Konopleva, Nitin Jain, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2023-174269

Published: 2023

Journal Articles

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Jacqueline S. Garcia, Eric S. Winer, Ilene Galinsky, Julie Bergeron, Julie Asch, Matthew D. Seftel, Richard M Stone, Marlise R. Luskin, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 4238.

https://doi.org/10.1182/blood-2023-181014

Published: 2023

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults

Marlise R. Luskin, Mark Alan Murakami, Julia Keating, Eric S. Winer, Jacqueline S. Garcia, Maximilian Stahl, Martha Wadleigh, Yael Flamand, Donna S. Neuberg, Ilene Galinsky, Rebecca Leonard, Ella Hagopian, Chase M Weizer, Carlin McLanahan, Richard M Stone, Eunice S. Wang, Wendy Stock, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 965.

https://doi.org/10.1182/blood-2023-174246

Published: 2023

Journal Articles

Methods of Estimating Renal Function for Use in Clinical Trial Eligibility Criteria Widely Vary in Phase II and III Clinical Trials in Acute Myeloid Leukemia

Priyanka Pullarkat, Yael Flamand, Harish Seethapathy, Meghan Sise, Andrew M. Brunner, Amir T. Fathi, Rupa Narayan

Blood (2023) 142 (Supplement 1): 3727.

https://doi.org/10.1182/blood-2023-191110

Published: 2023

Journal Articles

A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults

Marlise R. Luskin, Shai Shimony, Julia Keating, Yael Flamand, Jacqueline S. Garcia, Rebecca Leonard, Thomas Reardon, Taylor Robertson, Chase M Weizer, Ilene Galinsky, Donna S. Neuberg, Richard M Stone, Eric S. Winer, Anthony G. Letai, Mark Alan Murakami, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 1509.

https://doi.org/10.1182/blood-2023-174216

Published: 2023

Journal Articles

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Blood (2023) 141 (15): 1884–1888.

https://doi.org/10.1182/blood.2022017686

Published: 2023

Includes: Supplemental data

Journal Articles

Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD high but Not FLT3-ITD low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Eric S. Winer, Yael Flamand, Rory Michael Shallis, Jessica M. Stempel, Aaron D Goldberg, Maximilian F. Stahl, Anand Ashwin Patel, Adam S Duvall, Yasmin Abaza, Timothy Seijung Oh, Karen Ma, Talha Badar, Mark R. Litzow, Vamsi Kota, Danielle Bradshaw, Hari S. Raman, Marlise R. Luskin, Richard M. Stone, Daniel J. DeAngelo

Blood (2022) 140 (Supplement 1): 6285–6287.

https://doi.org/10.1182/blood-2022-170587

Published: 2022

Journal Articles

Adolescent and Young Adults with ALL Who Complete Therapy on DFCI Consortium ALL Trials Have Excellent Long-Term Overall Survival

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Richard M. Stone, Daniel J DeAngelo, Marlise R. Luskin

Blood (2022) 140 (Supplement 1): 8901–8903.

https://doi.org/10.1182/blood-2022-159286

Published: 2022

Journal Articles

Body Mass Index Effect on Survival and Toxicities Differs between Age Groups Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials

Shai Shimony, Yael Flamand, Yannis K. Valtis, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Richard M. Stone, Martha Wadleigh, Donna S. Neuberg, Daniel J DeAngelo, Marlise R. Luskin

Blood (2022) 140 (Supplement 1): 3164–3165.

https://doi.org/10.1182/blood-2022-158348

Published: 2022

Journal Articles

Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium

Blood (2021) 138 (Supplement 1): 3396.

https://doi.org/10.1182/blood-2021-151313

Published: 2021

Journal Articles

Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic

Hari S. Raman, Yael Flamand, Marlise R. Luskin, Daniel J. DeAngelo, Richard M. Stone, Jacqueline S. Garcia, Martha Wadleigh, Anne Charles, Kevin Copson, R. Coleman Lindsley, Jr., Rahul S. Vedula, Eric S. Winer

Blood (2021) 138 (Supplement 1): 2291.

https://doi.org/10.1182/blood-2021-149692

Published: 2021

Journal Articles

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-136235

Published: 2020

Journal Articles

Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Jurjen Versluis, Yael Flamand, MS, Erika J. Haydu, MD PhD, Rahul S. Vedula, MD, Anne Charles, BS, Kevin Copson, MA, Ofir Wolach, MD, Pavan Bendapudi, MD, Roger Belizaire, MD PhD, Donna S. Neuberg, ScD, Marlise R Luskin, MDMS, R. Coleman Lindsley, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137741

Published: 2020

Journal Articles

Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001

Lynda M. Vrooman, MD, Yael Flamand, MS, Victoria Koch, BS, Melissa A. Burns, MD, Sarah M. Cronholm, BA, Sarah K. Hunt, BS, MPH, Peter D. Cole, MD, Lisa M. Gennarini, MD, Justine M. Kahn, MDMSc, Kara M. Kelly, MD, Bruno Michon, MD FRCPC, Donna S. Neuberg, ScD, Andrew E. Place, MDPhD, Thai Hoa Tran, MD, Jennifer J.G. Welch, MD, Kristen E. Stevenson, MS, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-138840

Published: 2020

Journal Articles

Distinct Clinical and Genetic Factors Predict Early Versus Late Mortality in AML Patients Undergoing Induction Chemotherapy

J. Erika Haydu, MD PhD, Yael Flamand, Rahul S. Vedula, MD, Jurjen Versluis, Anne Charles, BS, Kevin Copson, MA, Donna S. Neuberg, ScD, R. Coleman Lindsley, MD PhD, Marlise R Luskin, MDMS

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138817

Published: 2020

Journal Articles

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Blood (2019) 134 (Supplement_1): 2015.

https://doi.org/10.1182/blood-2019-126238

Published: 2019

NARROW

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Oral Chemotherapy Adherence in Pediatric Acute Lymphoblastic Leukemia (ALL): A Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 16-001

Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults

Methods of Estimating Renal Function for Use in Clinical Trial Eligibility Criteria Widely Vary in Phase II and III Clinical Trials in Acute Myeloid Leukemia

A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD high but Not FLT3-ITD low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Adolescent and Young Adults with ALL Who Complete Therapy on DFCI Consortium ALL Trials Have Excellent Long-Term Overall Survival

Body Mass Index Effect on Survival and Toxicities Differs between Age Groups Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials

Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium

Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001

Distinct Clinical and Genetic Factors Predict Early Versus Late Mortality in AML Patients Undergoing Induction Chemotherapy

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only